MedTrace Logo

A Pharmacokinetic Study of an Experimental Paracetamol Formulation

NCT01476176 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-11-24

No results posted yet for this study

Summary

This PK study is designed to show bioequivalence between the study treatments.

Conditions

  • Headache, Tension-Type

Interventions

DRUG

Experimental paracetamol

experimental paracetamol with caffeine

DRUG

Paracetamol marketed formulation

marketed formulation containing caffeine

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01476176 on ClinicalTrials.gov